BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Esmya ulipristal Acetate regulatory update

EMA's CHMP issued a positive opinion recommending approval of Esmya ulipristal acetate from Gedeon's Richter's PregLem S.A. subsidiary to treat moderate to severe uterine fibroids in women of reproductive age. Esmya is a selective progesterone receptor modulator (SPRM). Richter gained Esmya through...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >